These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 10854162

  • 1. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo.
    Crowe JE, Randolph V, Murphy BR.
    Virus Res; 1999 Jan; 59(1):13-22. PubMed ID: 10854162
    [Abstract] [Full Text] [Related]

  • 2. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus.
    Hsu KH, Crowe JE, Lubeck MD, Davis AR, Hung PP, Chanock RM, Murphy BR.
    Vaccine; 1995 Apr; 13(5):509-15. PubMed ID: 7543716
    [Abstract] [Full Text] [Related]

  • 3. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees.
    Crowe JE, Bui PT, Davis AR, Chanock RM, Murphy BR.
    Vaccine; 1994 Jul; 12(9):783-90. PubMed ID: 7975856
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.
    Crowe JE, Collins PL, London WT, Chanock RM, Murphy BR.
    Vaccine; 1993 Nov; 11(14):1395-404. PubMed ID: 8310760
    [Abstract] [Full Text] [Related]

  • 6. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
    Whitehead SS, Hill MG, Firestone CY, St Claire M, Elkins WR, Murphy BR, Collins PL.
    J Virol; 1999 Dec; 73(12):9773-80. PubMed ID: 10559287
    [Abstract] [Full Text] [Related]

  • 7. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization.
    Crowe JE, Bui PT, Siber GR, Elkins WR, Chanock RM, Murphy BR.
    Vaccine; 1995 Jun; 13(9):847-55. PubMed ID: 7483808
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
    Whitehead SS, Firestone CY, Karron RA, Crowe JE, Elkins WR, Collins PL, Murphy BR.
    J Virol; 1999 Feb; 73(2):871-7. PubMed ID: 9882287
    [Abstract] [Full Text] [Related]

  • 10. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N, Amaro-Carambot E, Liang B, Surman S, Lingemann M, Yang L, Collins PL, Munir S.
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [Abstract] [Full Text] [Related]

  • 11. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation.
    Randolph VB, Kandis M, Stemler-Higgins P, Kennelly MS, McMullen YM, Speelman DJ, Weeks-Levy C.
    Virus Res; 1994 Sep; 33(3):241-59. PubMed ID: 7985411
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.
    Karron RA, Wright PF, Crowe JE, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR.
    J Infect Dis; 1997 Dec; 176(6):1428-36. PubMed ID: 9395351
    [Abstract] [Full Text] [Related]

  • 13. Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics.
    Luongo C, Winter CC, Collins PL, Buchholz UJ.
    J Virol; 2012 Oct; 86(19):10792-804. PubMed ID: 22837193
    [Abstract] [Full Text] [Related]

  • 14. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate.
    Firestone CY, Whitehead SS, Collins PL, Murphy BR, Crowe JE.
    Virology; 1996 Nov 15; 225(2):419-22. PubMed ID: 8918930
    [Abstract] [Full Text] [Related]

  • 15. Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.
    Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, Siberry GK, Rexroad V, Valentine M, Perlowski C, Schappell E, Thumar B, Luongo C, Barr E, Aziz M, Yogev R, Spector SA, Collins PL, McFarland EJ, Karron RA, International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1114 Study Team.
    J Infect Dis; 2018 Apr 11; 217(9):1338-1346. PubMed ID: 29509929
    [Abstract] [Full Text] [Related]

  • 16. Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primates.
    Crowe JE, Bui PT, Firestone CY, Connors M, Elkins WR, Chanock RM, Murphy BR.
    J Infect Dis; 1996 Apr 11; 173(4):829-39. PubMed ID: 8603960
    [Abstract] [Full Text] [Related]

  • 17. A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.
    Hall SL, Sarris CM, Tierney EL, London WT, Murphy BR.
    J Infect Dis; 1993 Apr 11; 167(4):958-62. PubMed ID: 8383726
    [Abstract] [Full Text] [Related]

  • 18. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature.
    Luongo C, Winter CC, Collins PL, Buchholz UJ.
    J Virol; 2013 Feb 11; 87(4):1985-96. PubMed ID: 23236065
    [Abstract] [Full Text] [Related]

  • 19. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap-Nutt A, Collins PL, Munir S.
    J Virol; 2015 Sep 11; 89(18):9499-510. PubMed ID: 26157122
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.